FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
Links shared publicly online about this topic.
- 452total visits
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
View full resource at novartis.com
Most Recently Shared on March 9, 2011 at 2:40 pm By:
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD - http://ow.ly/4aQ4K
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149... -- EAST HANOVER, N.J., March 8, 2011 /PRNewswire/ --
prnewswire.com — “FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD. - Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149 - COPD is a progressive and life-threatening lung” View full resource at prnewswire.com
Most Recently Shared on March 9, 2011 at 3:42 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator Indacaterol http://t.co/E2ttppR
Advertisement
